Home › Research › Treatments
Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease
Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, Tudor IC, Gregg K et al.. Journal of Alzheimer's disease : JAD, 2016-01-01
Topic: Amyloid, tau and blood-test diagnosis
Background Bapineuzumab, an anti-amyloid-β monoclonal antibody, was evaluated in two placebo-controlled trials in APOE*ɛ4 carriers and noncarriers, respectively, with Alzheimer's disease. Objectives A volumetric magnetic resonance imaging substudy was performed to determine if bapineuzumab altered brain volume rate of change. Methods Bapineuzumab dosages included 0.5 mg/kg in carriers and 0.5 or 1.0 mg/kg in noncarriers, every 13 weeks for 78 weeks. Volumetric outcomes included annualized brain, ventricular, and mean hippocampal boundary shift integrals (BBSI; VBSI; HBSI) up to Week 71. Treatment differences were estimated using mixed models for repeated measures. Results For BBSI and HBSI, there were no significant treatment-related differences within either study, but, compared to pooled carriers and noncarriers receiving placebo, noncarriers receiving1.0 mg/kg bapineuzumab had greater increases in these measures. Bapineuzumab-treated patients showed significantly greater VBSI rates compared with placebo for 0.5 mg/kg in carriers and 1.0 mg/kg (but not 0.5 mg/kg) in noncarriers. Conclusions Bapineuzumab produced an increase in ventricular volume compared with placebo. Etiology for this increase is unclear but may be related to amyloid-β clearance or its consequences.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Novak, G., Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., et al. (2016). Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-150448
Vancouver
Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, et al. Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2016. doi:10.3233/jad-150448. PMID: 26639957.
BibTeX
@article{novak2016-26639957,
author = {Novak, G. and Fox, N. and Clegg, S. and Nielsen, C. and Einstein, S. and Lu, Y. and Tudor, I. C. and Gregg, K. and others},
title = {{Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2016},
doi = {10.3233/jad-150448},
pmid = {26639957},
url = {https://doi.org/10.3233/jad-150448}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results For BBSI and HBSI, there were no significant treatment-related differences within either study, but, compared to pooled carriers and noncarriers receiving placebo, noncarriers receiving1.0 mg/kg bapineuzumab had greater increases in these measures.
- Bapineuzumab-treated patients showed significantly greater VBSI rates compared with placebo for 0.5 mg/kg in carriers and 1.0 mg/kg (but not 0.5 mg/kg) in noncarriers.
- Conclusions Bapineuzumab produced an increase in ventricular volume compared with placebo.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Effect sizeor 1.0; or 0.5
- Evidence strengthLow
How this study scored 67/100
Published in a peer-reviewed journal, and it is a large phase 3 trial. Scored zero for sample size because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record and institution's track record, so those were left out: it earned 41 of the 61 points we could judge it on, which is 67 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26639957) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 41 / 61 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 41 of the 61 points we could judge it on is 67 out of 100. |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “moderate”
4 studies in the library carry the topic tag “moderate”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.